Opdualag is a first-in-class, fixed-dose dual immunotherapy combination treatment of the PD-1 inhibitor nivolumab and novel LAG-3-blocking antibody relatlimab
First and only FDA-approved treatment for seizures associated with CDKL5 deficiency disorder (CDD) in patients two years of age and older
The announcement follows recent authorization of the Company's mRNA COVID-19 vaccine in Australia and the European Union for children aged 6-11 years
Doctors at Yashoda Hospitals Hyderabad perform rare operation
EUROAPI listing on Euronext Paris will occur in H1 2022, despite volatile market conditions
The Karnataka Health Promotion Trust held a day-long session in New Delhi to address health care challenges
Prashant comes with over 17 years of experience in the health, health insurance and other allied healthcare sectors
Roche and its subsidiary, Tib Molbiol, confirm that it has tests for research use that identify the SARS-CoV-2 subvariants of concern, Omicron: BA.1, BA.1.1, BA.2, BA.2.2, BA.3 and Delta
First PARP inhibitor to demonstrate overall survival benefit in early breast cancer
To date, 30 crore vaccines have been produced as part of the commitment made to the Government of India
Subscribe To Our Newsletter & Stay Updated
